Intuniv is available as 1mg, 2mg, 3mg, and 4mg extended-release tablets The Food and Drug Administration (FDA) has approved a new update to the Intuniv (guanfacine; Shire) labeling regarding ...
Cytochrome P450 (CYP) proteins are responsible for breaking down more than 80% of all Food and Drug Administration (FDA) approved drugs, reducing their effectiveness. However, how to prevent CYPs from ...
Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindications Updated U.S. label ...
The majority of drug interactions today are attributed to the cytochrome P450 (CYP450) isoenzyme system. However, new data suggest that transport proteins also play a key role. One such transporter is ...
CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments of LVEF are required prior to and during treatment with ...
May 12, 2004 — Substantial increases in trazodone hydrochloride (Desyrel) plasma concentration may occur with concurrent dosing of the cytochrome P450 3A4 (CYP3A4) inhibitors ketoconazole, ritonavir, ...
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. Serious ...
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback